MYOCARDIAL REPOLARIZATION From gene to bedside

MYOCARDIAL REPOLARIZATION: From Gene to Bedside

Myocardial repolarization is a fundamental electrophysiological process that restores cardiac myocytes to their resting membrane potential after depolarization and contraction. It is essential for the rhythmic and coordinated beating of the heart. Disturbances in repolarization can predispose to malignant arrhythmias and sudden cardiac death, making this process a major focus of both basic cardiovascular research and clinical cardiology. Understanding myocardial repolarization from its genetic basis to bedside applications illustrates the translational journey from molecular mechanisms to patient care.

Cellular and Ionic Basis of Repolarization

At the cellular level, myocardial repolarization corresponds mainly to phases 1, 2, and 3 of the cardiac action potential. After rapid depolarization (phase 0), repolarization begins with transient outward potassium currents, followed by a plateau phase where inward calcium currents balance outward potassium currents. Final repolarization is driven predominantly by delayed rectifier potassium currents. The precise timing and balance of these ionic currents determine action potential duration and refractoriness, which in turn govern heart rate, conduction, and susceptibility to arrhythmias.

Different regions of the heart—atria, ventricles, Purkinje fibers, and epicardial versus endocardial layers—display distinct repolarization characteristics. This heterogeneity is physiologically important, but excessive dispersion of repolarization can create a substrate for reentry and ventricular arrhythmias.

Genetic Regulation of Repolarization

The molecular foundation of myocardial repolarization lies in genes encoding cardiac ion channels, transporters, and their regulatory proteins. Potassium channel genes play a dominant role, as potassium currents are the principal drivers of repolarization. Mutations affecting these genes can alter current density or kinetics, leading to prolonged or abbreviated action potentials.

Inherited channelopathies exemplify how genetic alterations translate into clinical disease. Long QT syndrome results from delayed repolarization, reflected as QT interval prolongation on the surface electrocardiogram. Conversely, short QT syndrome arises from accelerated repolarization. Other conditions, such as Brugada syndrome, involve repolarization abnormalities particularly affecting the right ventricular outflow tract.

Genetic modifiers, epigenetic regulation, and gene–environment interactions further influence repolarization. Electrolyte disturbances, drugs, autonomic tone, and structural heart disease can unmask or exacerbate genetically determined repolarization defects, highlighting the complexity of translating genotype into phenotype.

Myocardial Repolarization on the Electrocardiogram

At the bedside, myocardial repolarization is primarily assessed using the surface electrocardiogram (ECG). The ST segment, T wave, and QT interval reflect different aspects of ventricular repolarization. QT interval duration, corrected for heart rate, is a key marker of repolarization abnormalities and arrhythmic risk.

T-wave morphology, dispersion of repolarization across leads, and dynamic changes during exercise or autonomic stimulation provide additional insights. Advances such as high-resolution ECG, vectorcardiography, and computerized ECG analysis have improved the detection of subtle repolarization abnormalities that may not be evident on routine recordings.

Clinical Implications and Risk Stratification

Abnormal myocardial repolarization is strongly associated with ventricular tachyarrhythmias, including torsades de pointes and ventricular fibrillation. Both congenital and acquired forms are clinically relevant. Acquired repolarization abnormalities often result from medications, especially antiarrhythmics and non-cardiac drugs that inadvertently block potassium channels, as well as from metabolic disturbances like hypokalemia or hypomagnesemia.

Risk stratification integrates genetic testing, ECG markers, clinical history, and sometimes invasive electrophysiological studies. Family screening is crucial in inherited repolarization disorders, allowing early identification of at-risk individuals before the occurrence of life-threatening events.

Therapeutic Approaches: From Mechanism to Management

Therapy targeting myocardial repolarization is guided by mechanistic understanding. Beta-blockers reduce sympathetic triggers and are first-line therapy in several inherited repolarization disorders. Avoidance of QT-prolonging drugs and correction of electrolyte imbalances are cornerstone strategies.

In high-risk patients, implantable cardioverter-defibrillators provide protection against sudden cardiac death. Emerging approaches include gene-specific therapies, personalized drug selection based on genetic background, and modulation of repolarizing currents through novel pharmacological agents.

Future Directions and Translational Perspectives

The study of myocardial repolarization continues to evolve with advances in genomics, induced pluripotent stem cell models, and computational electrophysiology. These tools enable patient-specific modeling of repolarization abnormalities and prediction of drug effects, bridging laboratory discoveries and individualized bedside care.

In summary, myocardial repolarization represents a continuum from genes encoding ion channels to clinical manifestations detectable on the ECG and managed at the bedside. A comprehensive understanding of this process is essential for preventing arrhythmias and improving cardiovascular outcomes, exemplifying the power of translational medicine in modern cardiology.